The Gastroesophageal Surgery Group performs about 70-80, 30-35 and 10 cases of surgery in a year for stomach cancer, esophageal cancer and other cancers respectively. We perform surgery with therapeutic strategy basically based on the clinical practice guidelines or the latest results of clinical trials.
For the treatment of esophageal cancer, we perform thoracoscopic / laparoscopic subtotal esophagectomy in principle in order to reduce patients’ burden. In some cases, we may perform atypical limited resection after taking each patient’s condition and wish into account.
For the treatment of stomach cancer, we perform laparoscopic surgery for patients with stage I cancer complying with the guidelines.
For other cancers, we also perform proactively laparoscopic surgery based on the patients’ wish and conditions.
Furthermore, we try to reduce patients’ invasion by pure laparoscopy and reduced port surgery.
In addition, through the proactive intervention of multidisciplinary nutritional support team, we aim at early recovery from postoperative invasion using enteral nutrition or supplementary nutrition, and both radical cure and QOL under the nutritional management during chemotherapy.

We cover a wide spectrum of diseases ranging from large intestine to anus. In particular, we have a lot of experience in restorative proctocolectomy for rectum cancer, and we started intersphincteric resection (ISR), which is the latest procedure of restorative proctocolectomy, in 2000. The team, which consists of a WOC (Wound/Ostomy/Continence) nurse, pharmacist, rehabilitation therapist and dietitian, is engaged in the treatments for patients suffering from low anterior resection syndrome (LARS) which develops after rectum cancer operation. We perform minimally invasive operation in principle, and besides, robot-assisted surgery with “Da Vinci System” as well as laparoscopic surgery.
We also have a lot of experience in rectal prolapse which is one of the most common functional disorders. We chose the optimal surgical procedure based on each patient’s condition and have had a good outcome. We provide many patients with satisfaction.

Our team was certified as a type-A training facility for advanced technique of hepato-biliary-pancreatic surgery. We proactively perform laparoscopic hepato-biliary-pancreatic surgery, which is a radical, less invasive and low burden surgical treatment, as well as the surgery categorized into higher difficulty level. In particular, we started laparoscopic hepatectomy (for hepatocellular cancer and metastatic liver cancer) in 1993 and gain global recognition as a pioneer in this country. Many surgeons from home and abroad have visited us to observe our advanced procedures. We proactively instruct other medical facilities and try to disseminate the surgical procedures. Furthermore, since 2018, we have run a non-profit organization, Endoscopic Liver Surgery Study Group, in which Prof. Hironori Kaneko serves as a chief director. Laparoscopic surgery is expected to enable early recovery, short hospitalization period and early social reintegration compared with laparotomy. Meanwhile, we believe that the long-term outcome of laparoscopic surgery compares favorably with laparotomy, and conduct a multicenter clinical trial to evaluate the safety.